Experimental drug entinostat tested for rare abdominal tumors – study halted early
NCT ID NCT03211988
First seen Mar 04, 2026 · Last updated May 13, 2026 · Updated 9 times
Summary
This study tested a drug called entinostat in people with advanced abdominal neuroendocrine tumors that had come back or stopped responding to standard treatments. Only 5 people took part, and the study was stopped early. The goal was to see if the drug could shrink tumors or slow the disease, but results are limited due to the small size and early termination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
Conditions
Explore the condition pages connected to this study.